Press Releases and Statements

CHPA’s President and CEO Scott Melville released the below statement today following the Senate HELP Committee’s Markup of S.4348, the FDA Safety and Landmark Advancement (FDASLA) Act of 2022:

Awareness of acetaminophen safe use and the risks of using too much remains high, indicating that ongoing education is critical to continued progress.

The Consumer Healthcare Products Association (CHPA) issued a statement from Duffy MacKay, Senior Vice President of Dietary Supplements, regarding a report from the U.S. Centers for Disease Control and Prevention (CDC) on Pediatric Melatonin Ingestions—United States, 2012-2021.

CHPA’s President and CEO, Scott Melville, released a statement in response to the introduction of the FDA Safety and Landmark Advancement (FDASLA) Act of 2022.

CHPA’s President & CEO, Scott Melville, released a statement in response to the FDA Safety and Landmark Advancement (FDASLA) Act of 2022.

CHPA has issued a statement in response to a recent, observational NSAID study published in the journal Science Translational Medicine.

The Consumer Healthcare Products Association (CHPA) today announced the hiring of Logan Tucker as Director of Communications and Media Relations.

CHPA President and CEO Scott Melville released a statement in response to Senator Durbin’s and Senator Braun’s Introduction of the Dietary Supplement Listing Act of 2022.

CHPA President and CEO Scott Melville released a statement today following the recent passing of former U.S. Senator Orrin Hatch.

The Consumer Healthcare Products Association applauds the confirmation of Judge Ketanji Brown Jackson to the United States Supreme Court.

The Consumer Healthcare Products Association issued a statement from President and CEO Scott Melville regarding the Food and Drug Administration’s (FDA) fiscal year 2023 budget request.

New data-driven tool will help CHPA educate stakeholders on the role of dietary supplements in healthcare.